Roivant’s shares rose 15.1% after the company reported $31 million in initial LISRAYA revenue and said its IMVT-1402 rheumatoid arthritis study met its Period 2 primary endpoint. The positive updates were tempered by management’s decision not to advance the Sjögren’s program, while it cautioned that the launch is early and September-quarter revenue benefited from pharmacy stocking.
Roivant's stock edged up modestly by 1.7% following a quiet quarter that met expectations without delivering clear catalysts to drive a stronger move. Investors appear to be in a wait-and-see mode ahead of several key data readouts and potential product launches slated for the second half of 2026.